

QR Pharma, Inc. to Present Corporate Update at 23rd Annual BioCentury NewsMakers Conference

--One of Fourteen Private Companies Selected to Present--

Berwyn, PA, September 9, 2016 — [QR Pharma, Inc.](#), a privately held Phase 2 biopharmaceutical company developing novel therapies for the treatment of Alzheimer's, Parkinson's and other neurodegenerative diseases, today announced that [Maria Maccacchini, Ph.D.](#), President and CEO, will present a corporate update at the [23rd Annual BioCentury NewsMakers](#) in the Biotech Industry Conference at 3:00 PM ET on September 9, 2016 at the Millennium Broadway Hotel & Conference Center in New York, NY. Dr. Maccacchini will also be participating in 1x1 meetings with investors and industry executives.

About QR Pharma, Inc.

Headquartered in Berwyn, Pennsylvania, QR Pharma, Inc. is a clinical-stage specialty pharmaceutical company committed to developing therapeutics with novel approaches for the treatment of cognitive impairment in neurological disorders.

QR is currently developing Posiphen as a disease-modifying drug for acute as well as chronic neurodegeneration and BNC for advanced Alzheimer's disease. For more information on QR Pharma, please visit the company's website, www.qrpharma.com

Contact: Maria Maccacchini
Tel: 610-727 3710
Fax: 610 727 4001
maccacchini@qrpharma.com
www.qrpharma.com